Stockreport

Capricor +23% after trial results accepted for presentation [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Capricor +23% after trial results accepted for presentationHOPE-1 is a randomized Phase I/II 12-month clinical trial that evaluated a single dose of CAP-1002, a cell-bas [Read more]